- Home
- RPTX vs DRRX Comparison
RPTX vs DRRX Comparison
Compare RPTX & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- DRRX
- Stock Information
- Founded
- RPTX 2016
- DRRX 1998
- Country
- RPTX Canada
- DRRX United States
- Employees
- RPTX N/A
- DRRX N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- DRRX Health Care
- Exchange
- RPTX Nasdaq
- DRRX Nasdaq
- Market Cap
- RPTX 69.2M
- DRRX 59.3M
- IPO Year
- RPTX 2020
- DRRX 2000
- Fundamental
- Price
- RPTX $1.69
- DRRX $1.91
- Analyst Decision
- RPTX Strong Buy
- DRRX Hold
- Analyst Count
- RPTX 3
- DRRX 1
- Target Price
- RPTX $4.50
- DRRX N/A
- AVG Volume (30 Days)
- RPTX 91.2K
- DRRX 501.2K
- Earning Date
- RPTX 11-06-2025
- DRRX 08-12-2025
- Dividend Yield
- RPTX N/A
- DRRX N/A
- EPS Growth
- RPTX N/A
- DRRX N/A
- EPS
- RPTX N/A
- DRRX N/A
- Revenue
- RPTX $250,000.00
- DRRX $1,657,000.00
- Revenue This Year
- RPTX N/A
- DRRX N/A
- Revenue Next Year
- RPTX N/A
- DRRX $673.00
- P/E Ratio
- RPTX N/A
- DRRX N/A
- Revenue Growth
- RPTX N/A
- DRRX N/A
- 52 Week Low
- RPTX $0.89
- DRRX $0.48
- 52 Week High
- RPTX $4.07
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- RPTX 66.56
- DRRX 73.30
- Support Level
- RPTX $1.66
- DRRX $1.86
- Resistance Level
- RPTX $1.60
- DRRX $1.96
- Average True Range (ATR)
- RPTX 0.06
- DRRX 0.03
- MACD
- RPTX 0.01
- DRRX -0.04
- Stochastic Oscillator
- RPTX 80.95
- DRRX 50.00
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.